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Abstract
Background: Colorectal cancer (CRC) is one of the most common causes of cancer death
throughout the world. In this work our aim was to study the role of the phosphoserine
aminotransferase PSAT1 in colorectal cancer development.
Results: We first observed that PSAT1 is overexpressed in colon tumors. In addition, we showed
that after drug treatment, PSAT1 expression level in hepatic metastases increased in non responder
and decreased in responder patients.
In experiments using human cell lines, we showed that ectopic PSAT1 overexpression in colon
carcinoma SW480 cell line resulted in an increase in its growth rate and survival. In addition,
SW480-PSAT1 cells presented a higher tumorigenic potential than SW480 control cells in
xenografted mice. Moreover, the SW480-PSAT1 cell line was more resistant to oxaliplatin
treatment than the non-transfected SW480 cell line. This resistance resulted from a decrease in
the apoptotic response and in the mitotic catastrophes induced by the drug treatment.
Conclusion: These results show that an enzyme playing a role in the L-serine biosynthesis could
be implicated in colon cancer progression and chemoresistance and indicate that PSAT1 represents
a new interesting target for CRC therapy.
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Background
Colorectal cancer (CRC) is the fourth cause of cancer-
related deaths worldwide and 945 000 new cases are
detected every year. Fifteen percent of CRC are hereditary,
whereas the other 85% are considered as being sporadic.
CRC development involves multiple genetic events like
genetic mutations and aberrant gene expression that have
been well documented by Vogelstein and colleagues [1].
These authors proposed a multistep model leading to
colorectal tumorigenesis. One of the first genetic muta-
tions in CRC development is a mutation in the APC/β-cat-
enin pathway, resulting in adenoma formation. Then, a
mutation in another growth pathway, either Ki-Ras/BRAF,
Smad4/TGFβ, PI3K, or TP53/BAX occurs when the ade-
noma becomes larger, leading to carcinoma. Besides this
well-characterized model, it appears that a large number
of genes (mainly identified by microarray) could present
an altered expression pattern and may play a role in initi-
ation, progression, and drug response of CRC [2].
CRC primary treatment is surgery but the risk of recur-
rence due to undetected micrometastases is high. To
reduce this risk, chemotherapy can be administrated after
removal of the primary tumor in the advanced stages.
Combination of the antimetabolite 5-fluorouracil (5-FU)
and folinic acid with the topoisomerase I inhibitor iri-
notecan and/or the platinum compound oxaliplatin
appears to be the most effective treatment, with a response
rate between 40 and 50% [3,4]. Recently, new biological
therapeutic agents like the monoclonal antibodies cetuxi-
mab and bevacizumab have emerged and improved the
clinical outcome of patients with colorectal metastatic
cancer [5,6]. However, since 50% of patients are still not
responsive to chemotherapy because of drug resistance,
prediction of patient response and development of alter-
native treatments is of prime importance in the CRC field.
Using genome-wide transcriptional analysis, several
authors have identified new predictive markers and thera-
peutic targets implicated in the development and drug
response of colon carcinoma cells [7-10].
The phosphoserine aminotransferase PSAT1 is an enzyme
implicated in serine biosynthesis and has been linked
with cell proliferation in vitro [11]. Two studies reported
that PSAT1 mRNA is overexpressed in colon adenocarci-
noma [12] and increases with tumor stage in colon cancer
[13]. It was also shown that high PSAT1 mRNA levels in
breast cancer are associated with a poor clinical response
to endocrine therapy [14]. These studies showed that
there is a clear rational for studying PSAT1 as a pro-prolif-
erative and pro-survival factor in the context of colon can-
cer.
This report addresses the role of the phosphoserine ami-
notransferase PSAT1 in CRC. We first observed that PSAT1
was overexpressed in tumor samples from CRC patients,
and that its level of overexpression after chemotherapy is
correlated with poor regression of the tumour metastases.
Then, we demonstrated that PSAT1 ectopic expression
promoted cell growth and made the cells more resistant to
oxaliplatin treatment. Overall, the data presented here
identify PSAT1 as a potential new therapeutic target in
CRC.
Results
PSAT1 is overexpressed in colorectal tumor samples
To investigate the role of PSAT1 in colorectal cancer, we
first analyzed the PSAT1 mRNA expression in tumors
from 29 patients with advanced colorectal cancer. In Fig.
1 are shown the expression levels of PSAT1 measured both
by Affymetrix (Fig. 1A) and Q-PCR (Fig. 1B) experiments
in 23 colon tumors (TC), 22 hepatic metastases (HM) and
17 normal mucosas (NC). Using both methods, we found
that the phosphoserine aminotransferase PSAT1, was sig-
nificantly overexpressed in tumors (NC vs TC, p < 0.0001
and NC vs HM, p < 0.0001). The fold change was less
important when measured by Q-PCR than by microarray
(3.0 compared to 7.9 for TC/NC and 2.9 compared to 7.2
for HM/NC). This can be explained by the difference in
sensitivity of each technique or by the variation of the
microarray data which were performed only once for each
sample, whereas the Q-PCR measurements were done in
triplicates.
We then investigate the PSAT1 expression level in colon
cancer cell lines. Semiquantitative RT-PCR analysis of
PSAT1 mRNA level in HT29, SW620, SW480, SW48,
LS174T and WiDR cell lines was performed. mRNA level
in normal and tumoral colon from samples showed in fig-
ure 1B were also included as an example of non-cancerous
and cancerous intestinal epithelial cells respectively (Fig.
1C). PSAT1 was expressed in all the colon cancer cells
tested, with the lowest expression level found in normal
colon.
Increase of PSAT1 expression after chemotherapy is linked 
with tumor progression in CRC patients
To determine whether the high PSAT1 mRNA levels is
associated with clinical response, we explored the correla-
tion between PSAT1 expression levels and tumor regres-
sion after chemotherapy. Microarray and RT-Q-PCR
analyses were performed with mRNA extracted from
hepatic metastases from four patients with metastatic
colon cancer before and after FOLFIRI treatment (leucov-
orin, 5-FU and irinotecan). We defined the percentage of
regression for each patient on the basis of anatomic indi-
cators (tumor lesions) according to WHO criteria. Among
the four patients, one was highly sensitive to FOLFIRI,
with a tumoral regression close to 85%; two were partially
sensitive, with tumoral regression ranging from 65% toMolecular Cancer 2008, 7:14 http://www.molecular-cancer.com/content/7/1/14
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25%; and one was considered as resistant, with no meas-
urable tumoral regression. The PSAT1 expression ratio
(ratio of the mRNA level in hepatic metastases after to
before FOLFIRI treatment) for each patient has been cal-
culated using Affymetrix microarrays (data not shown)
and RT-Q-PCR values (Fig. 1D). For the patient showing
the best tumor regression (patient 4), the PSAT1 ratio was
very low. For patients showing mild tumor regression
(patients 2 and 3), the PSAT1 expression ratio increased,
and this increase was greater when tumor regression was
poor. Finally, the patient showing no tumor regression
(patient 1) had a high PSAT1 ratio. This inverse correla-
tion between clinical progression and the PSAT1 ratio in
tumor specimens was obtained using both RNA quantifi-
cation methods, Affymetrix microarrays (data not shown)
and RT-Q-PCR (Fig. 1D). This suggests that an increase in
PSAT1 overexpression after chemotherapy may be corre-
lated with a poor treatment response.
PSAT1 mRNA expression level and clinical correlation between PSAT1 mRNA expression level and tumoral regression Figure 1
PSAT1 mRNA expression level and clinical correlation between PSAT1 mRNA expression level and tumoral 
regression. Box plot representation of PSAT1 mRNA levels determined by Affymetrix technology (A) and by semiquantitative 
PCR (B). NC: normal colon (17 samples). TC: tumor colon (23 samples). HM: hepatic metastasis (22 samples). The box for 
each gene represents the interquartile range (25–75th percentile) and the line within this box is the median value. Bottom and 
top bars of the whisker indicate the 10th and 90th percentiles, respectively. Outlier values are indicated (closed squares). The 
clinical data for the 29 patients included in this study are detailed in Table 1. C, PSAT1 mRNA levels determined by semiquan-
titative PCR in various cell lines. NC: normal colon (17 samples). TC: tumor colon (23 samples). D, PSAT1 mRNA expression 
in hepatic metastasis before (NT: not treated) and after (T: treated) chemotherapy determined by semi-quantitative RT-PCR. 
Patients' response to treatment (tumor regression) and PSAT1 expression after therapy are negatively correlated (Pearson's 
test, p = -0.76).Molecular Cancer 2008, 7:14 http://www.molecular-cancer.com/content/7/1/14
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SW480-PSAT1 colon carcinoma cells present an advantage 
in proliferation and survival in low serum conditions
To determine the PSAT1 overexpression effect in human
adenocarcinoma cells, we stably transfected PSAT1 in
SW480 using the Flp-In System. In this system, the recipi-
ent cell line contains a single integrated Flp recombina-
tion site where the ectopically expressed gene can be
inserted. This system produces isogenic cell lines in which
all the transfected clones produce equivalent levels of the
protein of interest, thereby eliminating the need to ana-
lyze multiple subclones. As a control, we used the SW480-
FlpIn cell line, stably transfected with the empty vector to
avoid the possibility of observing a phenotype caused
only by an integration effect. PSAT1 was detected by
immunoblotting using an anti-PSAT antibody. Fig. 2A
shows that PSAT1 was endogenously expressed in the con-
trol SW480-FlpIn cells with an apparent molecular weight
of 40 000. In the stable SW480-PSAT1 clone, the ectopic
PSAT1 protein displayed a higher molecular weight of 45
000. This higher molecular weight for the transfected pro-
tein is due to the presence of the C-terminal V5 tag in our
construct. Two forms of human phosphoserine ami-
notransferase have been reported, PSAT1α and PSAT1β,
encoding, respectively, a protein of 35 200 and 40 000.
Fig. 2A shows that the SW480-FlpIn and SW480-PSAT1
cells only expressed the PSAT1β form, which has been
reported to be the physiologically functional enzyme.
We first analyzed the growth rates of the SW480-FlpIn and
SW480-PSAT1 cells. The proliferation assay showed that
SW480-PSAT1 grew faster than SW480-FlpIn in standard
culture conditions (10% of FBS), with an average dou-
bling time of 22.05 ± 1.58 hours and 30.54 ± 3.88 hours,
respectively (data not shown). Thus, expression of PSAT1
in the SW480 cells conferred a proliferative advantage
since the doubling time decreased by about eight hours.
The same results were obtained in HEK293 epithelial kid-
ney cells (data not shown), indicating that this effect is
not cell line dependent. In low-serum medium (1% of
FBS), proliferation of both cell lines decreased but
SW480-PSAT1 grew still faster than SW480-FlpIn, with an
average doubling time of 36.3 ± 5.9 hours and 53.5 ± 6.5
hours, respectively (Fig. 2B). SW480-PSAT1 growth rate in
low-serum conditions is comparable with the SW480-
FlpIn's in 10% FBS (36.3 hours compared to 30.54 hours,
respectively) indicating that SW480-PSAT1 showed par-
tial growth factor independence, which is a hallmark of
malignancy.
SW480-PSAT1 colon carcinoma cells present a high 
tumorigenic potential in tumor xenografts
To evaluate the tumorigenic potential of SW480-FlpIn
and SW480-PSAT1, we compared the ability of both cell
lines to give rise to subcutaneous tumors in nude mice.
Cells were injected subcutaneously into the left flank for
SW480-FlpIn and the right flank for SW480-PSAT1 of the
same nude mouse and tumor growth was evaluated by
measuring the tumor size at different times. As shown in
Fig. 2C and 2D, the SW480-PSAT1 tumor grew much
faster than the SW480-FlpIn tumor, indicating that colon
cancer cells overexpressing PSAT1 proliferated faster in
vivo, as was also the case in vitro. In addition, 18 days after
cell inoculation, 86% of SW480-PSAT1 grafted mice
developed a tumor whereas only 33% of SW480-FlpIn
grafted mice developed one (Fig. 2E). Moreover, even
after 30 days only half of the mice developed a tumor
when grafted with SW480-FlpIn whereas all the mice
grafted with SW480-PSAT1 developed a tumor after only
22 days.
SW480 colon carcinoma cells overexpressing PSAT1 are 
more resistant to drug treatment
We further characterized the SW480-FlpIn and SW480-
PSAT1 cell lines for their responses to chemotherapy. Both
cell lines were treated with the three drugs commonly
used in the treatment of colon cancer: 5-FU, SN38 (the
Table 1: Clinical data for patient samples.
Number Percentage
Gender
Masculine 18 62.1%
Feminine 11 37.9%
Age
Median 60.2
Range (45.1: 76.0)
Tumor Location
Colon Right 1 3.4%
Colon transverse 2 6.9%
Colon Left 20 69.0%
Rectum 3 10.3%
Recto-sigmoid 3 10.3%
Histological Type
ADK well diff 11 37.9%
ADK diff 11 37.9%
ADK not well diff 3 10.3%
ADK (diff) 3 10.3%
Missing 1
N
Nx 1 3.4%
N0 7 24.1%
N1 5 17.2%
N2 16 55.2%
T
Tx 1 3.4%
T3 19 65.5%
T4 9 31.0%
OMS initial
01 0 4 5 . 5 %
11 2 5 4 . 5 %
missing 7
Abbreviation: ADK, adenocarcinoma, N, node, T, tumor.Molecular Cancer 2008, 7:14 http://www.molecular-cancer.com/content/7/1/14
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active metabolite of irinotecan), and oxaliplatin. The cells
were exposed for 72 hours to increasing concentrations of
each drug and their growth was measured using the sul-
forhodamine B assay. When treated with SN38, SW480-
PSAT1 cells (IC50 = 10.3 ± 0.57 nM) were only marginally
more resistant (p = 0.05) than the control SW480-FlpIn
(IC50 = 9 ± 0.11 nM), indicating that PSAT1 is not playing
a role in SN38 resistance (data not shown). For 5-FU, the
IC50 values of the SW480-FlpIn and SW480-PSAT1 cells
were respectively 2.98 ± 0.86 μM and 4.27 ± 0.42 μM
(data not shown) but the difference is not significant (p =
0.1), showing that PSAT1 is not implicated in resistance to
5-FU. Finally, we observed that oxaliplatin treated cells
displayed IC50 values of 0.54 ± 0.06 μM for SW480-FlpIn
and 0.81 ± 0.13 μM for SW480-PSAT1 cells (Fig. 3A) (p =
0.014), and IC70 values were 0.93 ± 0.13 and 2.19 ± 0.51
respectively (Fig. 3A). These results indicate that SW480
cells overexpressing PSAT1 were more resistant to drug,
notably oxaliplatin, than the mock transfected cells.
We then compared the drug effect on cell cycle and apop-
tosis of SW480-FlpIn and SW480-PSAT1 cells, using drugs
concentrations corresponding to the IC70 value. Twenty
nM of SN38 during 72 hours induced a G2/M arrest with
a high number of polyploid cells (up to 38%) for both cell
lines (Fig. 3B). Following a 10 μM treatment of 5-FU, both
cell lines presented the same increase in the number of
cells in the G2/M phase and a diminution in the G0/G1
and S phases (Fig. 3C). These data indicate that SN38 and
5-FU effect on the cell cycle did not depend on PSAT1
Effect of PSAT1 overexpression on cell proliferation and tumor xenograft Figure 2
Effect of PSAT1 overexpression on cell proliferation and tumor xenograft. A, Western blot analysis of PSAT1 
expression in SW480-FlpIn and SW480-PSAT1 cell lines using anti-PSAT1 or anti-V5 antibodies. B, Growth curve of SW480-
FlpIn and SW480-PSAT1 cultured in low serum medium (1%). The curves are representative of three experiments. C, Repre-
sentative nude mice, SW480-FlpIn were injected subcutaneously into the left flank and SW480-PSAT1 into the right flank. D, 
Tumor volume evolution after a subcutaneous xenograft of SW480-FlpIn and SW480-PSAT1 in 7 athymic nude mice. E, In vivo 
tumorigenic frequency for SW480-FlpIn and SW480-PSAT cell lines. Ratios indicate the number of mice presenting an observ-
able tumor compared with the total number of mice observed. Numbers in parentheses indicate percentages.Molecular Cancer 2008, 7:14 http://www.molecular-cancer.com/content/7/1/14
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expression. Finally, 2 μM oxaliplatin induced a lost of the
S phase coupled with an enrichment of the G2/M phase,
and this phenotype was enhanced in SW480-PSAT1 cells
compared with SW480-FlpIn cells (Fig. 3D). Oxaliplatin
induced appearance of polyploid cells in SW480-FlpIn
(17%) but not in SW480-PSAT1 (4%). These data indicate
that PSAT1 does not seem to be implicated in cell cycle
changes after 5-FU and SN38 exposure but rather plays a
role in oxaliplatin-induced cell cycle modifications.
Cells in the subG1 phase are representative of late apop-
tosis. SN38- (Fig. 3B) and 5-FU- (Fig. 3C) induced apop-
tosis were comparable, with values for SW480-PSAT1 and
SW480-FlpIn, respectively, of 7% and 4% for SN38 and
12% and 17% for 5-FU. On the contrary, oxaliplatin
induced more apoptosis in SW480-FlpIn (10%) than in
the PSAT1 overexpressing SW480 (3%) (Fig. 3D).
PSAT1 effect on oxaliplatin resistance is mediated by cell 
death inhibition
Both cell lines were then characterized for drug induced
apoptosis by measurement of annexin V-positive and PI-
negative cells, representing early apoptosis (compared
with late apoptosis, quantified previously by counting the
Effect of PSAT1 overexpression on drug resistance and cell cycle progression Figure 3
Effect of PSAT1 overexpression on drug resistance and cell cycle progression. A, Comparison of growth inhibition 
(IC50) between SW480-FlpIn and SW480-PSAT1. Cell cycle distribution of SW480 and SW480-PSAT1 cells following treat-
ment with 20 nM SN38 (B), 10 μM 5-FU (C) and 2 μM oxaliplatin (D) for 72 hours. Cell cycle distribution was measured by 
propidium iodide staining with a FACScan flow cytometer. FACS profiles and the proportion of cells in each phase of the cell 
cycle are presented: cells with a high DNA content (black), cells in G2/M (white), S (grey), GO/G1 (white with black dots) and 
the subG1 phase (white and black slashes). Cells in subG1 represent cells in late apoptosis.Molecular Cancer 2008, 7:14 http://www.molecular-cancer.com/content/7/1/14
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subG1 cells). Cells were treated for 72 hours with either
10 μM of 5-FU, 20 nM of SN38, or 2 μM of oxaliplatin. As
shown in Fig. 4A, 5-FU and SN38 induced apoptosis did
not vary between SW480-FlpIn and SW480-PSAT1 cell
lines, in accordance with the results indicated above on
cells in subG1. Combined with the cell cycle data, it
appears that SW480-PSAT1 resistance to 5-FU is not due
to apoptosis resistance or cell cycle modification but
rather to a growth advantage or resistance to apoptosis-
independent cell death. Concerning oxaliplatin, SW480-
PSAT1 cells displayed less apoptosis (up to two times)
than the mock transfected SW480-FlpIn (Fig. 4A), and this
may explain in part the resistant phenotype (Fig. 3A).
To characterize more precisely the oxaliplatin induced
apoptosis, we used increasing amounts of the drug.
SW480-FlpIn and SW480-PSAT1 cells were treated for 72
hours with 1 μM, 2 μM and 3 μM of oxaliplatin. Both cell
lines displayed increased apoptosis as the oxaliplatin con-
centration increased, but SW480-PSAT1 showed for each
PSAT1 overexpression effects on cell death after drug treatment Figure 4
PSAT1 overexpression effects on cell death after drug treatment. A, Early apoptosis of SW480 and SW480-PSAT1 
cells following exposure to oxaliplatin (2 μM), SN38 (20 nM) and 5-FU (10 μM) for 72 hours. Apoptosis was determined by 
propidium iodide and Annexin V-FLUOS staining with a FACScan. B, Specific apoptosis of SW480 and SW480-PSAT1 cells fol-
lowing exposure to 1 μM, 2 μM, and 3 μM of oxaliplatin for 72 hours. C, Dead cell number in response to oxaliplatin treatment 
(1 μM, 2 μM and 3 μM). The number of dead cells was determined by counting the trypan blue stained cells.Molecular Cancer 2008, 7:14 http://www.molecular-cancer.com/content/7/1/14
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dose a 50% reduction of the apoptotic response compared
with SW480-FlpIn (Fig. 4B). We next investigated the total
number of dead cells in response to oxaliplatin treatment
to determine if apoptosis was the only mechanism of cell
death responsible for this drug toxicity. We counted the
trypan blue-labeled dead cells in a cell population treated
with oxaliplatin at 1 μM, 2 μM and 3 μM for 72 hours. As
shown in Fig. 4C, cell death increased with the oxaliplatin
concentration, and the SW480-PSAT1 population exhib-
ited a smaller number of dead cells than the control
SW480-FlpIn population, as was also the case when apop-
tosis was monitored (Fig. 4B). In addition, the total
number of dead cells was greater than the number of
apoptotic cells, and the difference between the two cell
lines was also higher than what we observed with apopto-
sis. This suggests that PSAT1 overexpression inhibited not
only the apoptotic response but also another cell death
mechanism induced by oxaliplatin treatment. Besides
apoptosis, it appears that mitotic catastrophe, autophagy,
and necrosis can participate in tumor cell death [15], indi-
cating that PSAT1 may play an inhibitory role in one of
these biological processes. The observation that SW480-
FlpIn cells treated with oxaliplatin displayed G2/M arrest
and appearance of polyploid cells (Fig. 3D) prompted us
to analyze the two phenomena in more detail.
To this end, SW480-FlpIn and SW480-PSAT1 cells were
treated with increasing concentrations of oxaliplatin
(from 0 to 8 μM) during 48 hours, and the cell cycle was
monitored by flow cytometry. The analysis presented in
Fig. 5A shows an increase in G2/M arrest with increasing
concentrations of oxaliplatin in SW480-FlpIn and
SW480-PSAT1 and polyploidy formation only in the
SW480-FlpIn cells. The number of cells with a DNA con-
tent greater than 4N was much lower in SW480-PSAT1
(4% at 8 μM) than in SW480-FlpIn (22% at 8 μM). Fur-
thermore, observation of cell morphology showed the
appearance of huge multinucleated cells with unusual
shapes consequent to oxaliplatin treatment (Fig. 5B).
These cells are similar to the multinucleate giant cells pre-
viously reported in curcumin-treated cells [16]. Such a
morphological feature along with appearance of high
DNA content is compatible with death through mitotic
catastrophe, a form of non-apoptotic cell death caused by
aberrant mitosis.
SW480 cells overexpressing PSAT1 are able to recover 
from a treatment with a high dose of oxaliplatin
To investigate the long-term implications of the reduced
cell death and growth inhibition in response to oxalipla-
tin, we evaluated the ability of the cells to grow after a
high dose treatment. The cells were exposed to oxaliplatin
for 72 hours, then washed and resuspended in growth
medium. We counted viable cells at the end of the oxali-
platin treatment (Fig. 6A, D0) and 3 days after drug
removal (Fig. 6A, D3). For oxaliplatin concentrations of 1
μM and 2 μM, SW480 mock transfected cells failed to
recover from treatment, as suggested by the fact that the
cell number at D3 was lower than the cell number at D0.
This was not the case for the SW480-PSAT1 cells, which
were able to grow between D0 and D3 (Fig. 6A). It must
be noted that the drug concentrations used in this assay
correspond to almost twice that of the IC50 determined
by the sulforhodamine assay, namely, 0.54 μM for
SW480-FlpIn and 0.81 μM for SW480-PSAT1, indicating
that the difference between cell lines was not simply due
to a difference in IC50 and may be called the "long-term
drug resistance effect". Indeed, under equitoxic conditions
(1  μM of oxaliplatin for SW480-FlpIn and 2 μM for
SW480-PSAT1, Fig. 6A), the control cell number contin-
ued to decrease after drug removal, whereas SW480 over-
expressing PSAT1 continued to grow. Concerning the 4
μM concentration, even though the number of SW480-
PSAT1 cells was greater than that of SW480-FlpIn, the
SW480-PSAT1 cells were not able to grow after drug
removal.
After treatment with 2 μM of oxaliplatin, we followed cell
growth for 11 days. As shown in Fig. 6B, the SW480-
PSAT1 cells started growing normally 7 days after the end
of the treatment, with a doubling time comparable to that
for non-treated cell. This was not the case for the control
cells which continued to decline after drug removal and
were all dead after 7 days, demonstrating that PSAT1 plays
a role in cell survival in the presence of oxaliplatin. This
was confirmed by observation of the cells by light micro-
scopy. As shown in Fig. 6C, the SW480-PSAT1 cells looked
healthier compared with the SW480-FlpIn cells and after
11 days they formed a layer in the dish. In addition, after
11 days, the cell cycle of SW480-PSAT1 returned to nor-
mal (data not shown).
Altogether, our data demonstrate that two mechanisms
may explain the in vitro resistance to oxaliplatin of adeno-
carcinoma cells overexpressing PSAT1. First, cells are more
resistant to oxaliplatin-induced cell death and, second,
cells are able to recover from the oxaliplatin induced G2/
M arrest.
Discussion
An important goal in colon cancer therapy is to overcome
drug resistance either by deciphering resistance mecha-
nisms or by identifying new drugs with synergistic effects
when administered with current treatments. In this study,
we observed that the phosphoserine aminotransferase
PSAT1 is overexpressed in colon carcinoma compared
with normal mucosa. Its overexpression enhances cell
proliferation even under low serum condition indicating
that PSAT1 may be implicated in cell survival under stress
conditions. In addition, we showed that PSAT1 is impli-Molecular Cancer 2008, 7:14 http://www.molecular-cancer.com/content/7/1/14
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Cell death resistance in response to oxaliplatin treatment Figure 5
Cell death resistance in response to oxaliplatin treatment. A, Proportion of viable cells after a 72 hour oxaliplatin 
treatment (0 to 8 μM) of SW480-FlpIn and SW480-PSAT1 cells with a high DNA content (black), in the G2/M phase (white), 
the S phase (grey), or the GO/G1 phase (white with black dots). B, Pictures of SW480-FlpIn and SW480-PSAT1 cell morphol-
ogy. Cells were either not treated or treated with 10 μM of oxaliplatin for 24 hours. Staining was done using either DAPI to 
visualize the nucleus or an anti-tubulin antibody to visualize the entire cell. Giant multinucleated cells are indicated by an arrow. 
Magnification ×63.Molecular Cancer 2008, 7:14 http://www.molecular-cancer.com/content/7/1/14
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cated in drug resistance and, in particular, we demon-
strated that the effect of PSAT1 on oxaliplatin resistance is
due to cell death inhibition.
PSAT1 belongs to subgroup IV of aminotransferases and
catalyses the conversion of 3-phosphohydroxypyruvate to
l-phosphoserine. PSAT1 regulates the biosynthesis of ser-
ine from intermediates of the glycolytic pathway, and its
activity is broadly distributed among the organs but is
increased in tissues with a high rate of cell turnover.
PSAT1 mRNA is expressed at high levels in the brain, liver,
kidney, and pancreas; but at low levels in the thymus,
prostate, testis, and colon [11]. Previously, two studies
reported that phosphoserine aminotransferase is overex-
pressed in colon adenocarcinoma [12] and increases with
tumor stage in colon cancer [13]. Moreover, Martens and
colleagues reported that PSAT1 is overexpressed in some
breast cancer samples and that this overexpression is asso-
ciated with unfavorable clinical outcome in patients
treated with the antiestrogen tamoxifen [14]. This last
result combined with ours suggests that PSAT1 overex-
pression is connected to therapy resistance.
It has been reported that treatment of adenocarcinoma
colon cells with SN-38, oxaliplatin or 5-FU induces G2/M
cell cycle arrest, [16-18], and our data showed that this is
Cell survival after high dose oxaliplatin treatment and release Figure 6
Cell survival after high dose oxaliplatin treatment and release. A, Number of viable cells determined after oxaliplatin 
treatment (1 μM, 2 μM, and 4 μM) of SW480 and SW480-PSAT1 cells. Oxaliplatin treatment lasted for three days and the first 
counting was done at the end of the three days treatment (D0). Cells were then washed and incubated in complete medium 
without oxaliplatin (release). Second counting was done three days after the oxaliplatin release (D3). Number of viable cells 
was determined by counting, excluding trypan blue stained cells. Data are the mean of three independent experiments. B, Cell 
survival analysis during the three days of oxaliplatin treatment (2 μM) followed by 11 days without drug. The number of viable 
cells was determined by counting, excluding trypan blue stained cells. Data are the mean of three independent experiments. C, 
Images of SW480-FlpIn and SW480-PSAT1 cell morphology. Day -3 corresponds to the first day of oxaliplatin treatment (2 
μM). Day 0 corresponds to the last day of oxaliplatin treatment. Days 3, 7, and 11 correspond to the number of days after the 
oxaliplatin release. Magnification ×10.Molecular Cancer 2008, 7:14 http://www.molecular-cancer.com/content/7/1/14
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also the case in PSAT1-overexpressing cells. However, in
the case of oxaliplatin, cell cycle modifications were
amplified by PSAT1 overexpression since, in the trans-
fected cell line; more cells were blocked in G2/M phase. In
addition, in oxaliplatin-treated SW480 cell cultures; there
was an accumulation of large cells with a high DNA con-
tent, as seen by FACS analysis and immunofluorescence
microscopy. This phenotype is reminiscent of a cell death
mechanism called mitotic catastrophe, which results from
aberrant mitosis and leads to the formation of large non-
viable cells with numerous micronuclei [19]. To date,
induction of mitotic catastrophes by oxaliplatin has not
been reported, but the fact that oxaliplatin causes DNA
strand breaks and G2/M arrest is in good agreement with
previously described mechanisms that induce mitotic
catastrophe [20]. We propose that oxaliplatin induced cell
death in SW480 cells is due to both apoptosis and mitotic
catastrophes and that the resistance phenotype of the
PSAT1 overexpressing cells results from a decrease in the
induction of both mechanisms. This suggests that preven-
tion of mitotic catastrophes could be a new mechanism
for drug resistance in colon adenocarcinoma cells.
The study reported herein suggest that PSAT1 may be a
gene whose expression pattern before and after treatment
is associated with poor response to FOLFIRI in colorectal
cancer patients. Our in vitro results indicating that PSAT1
overexpression impairs the effect of the chemotherapy fit
well with these clinical data. We are aware that data on
four clinical samples is not statistically significant and that
this result must be confirmed on more samples. We are
planning to collect such metastatic samples taken from
the same patient before and after drug therapy, especially
patients treated with FOLFOX (leucovorin, 5-FU and
oxaliplatin).
PSAT1 is implicated in catabolism, catalyzing the second
step in the biosynthesis of the amino acid serine [21]. The
serine synthesis pathway provides the precursors for cellu-
lar proliferation as it is required for the synthesis of purine
nucleotides. Knowing that PSAT1 is implicated in purine
nucleotide synthesis, one drug that could overcome
chemoresistance due to PSAT1 overexpression may be the
antimetabolite purine antagonist mercaptopurine (thio-
guanine), which inhibits several enzymes in the purine
synthesis pathway. This family of compounds is widely
used for autoimmune disorder and for patients with
chronic inflammatory bowel diseases [22].
It is interesting to note that among all the amino acids,
serine has an important role in cell proliferation [23]. This
was demonstrated for the first time in 1956 when McCoy
demonstrated that cells in culture grew better when serine
and glycine were added to the culture medium [24]. In
addition, it was shown by Snell [25] that 3PGHD activity
(enzyme that catalyses the initiating step in serine biosyn-
thesis) is increased in human colon carcinoma. These two
reports along with our data indicate that the L-serine syn-
thesis pathway may be important in colon tumor forma-
tion and growth and deserves further investigations.
Conclusion
In summary, our results point to PSAT1 as a novel gene
that stimulates colorectal cancer cells proliferation and
modulates chemotherapy sensitivity, both in vitro and in
vivo.
Methods
Cell lines, tissues and reagents
The tissues used in our study belong to a set of clinical
specimen already described [26].
Tumoral regression evaluation took into account meas-
urements of the target lesions according to WHO recom-
mendations for the evaluation of cancer treatment in solid
tumors. Using computed tomography scanning, meta-
static tumor size was estimated from bidimensional meas-
urements (the product of the longest diameter and the
longest perpendicular diameter) before and after every
four or six cycles of chemotherapy to calculate the percent
change from baseline. The study was approved by our
local ethical committee; all participating patients were
informed about the study and had to provide signed, writ-
ten, informed consent before enrollment.
SW480 human colon adenocarcinoma was purchased
from ATCC and was maintained in RPMI 1640 medium
supplemented with 10% fetal bovine serum (FBS) and 2
mM L-glutamine. SN38 was kindly provided by Sanofi-
Aventis. 5-Fluorouracile and oxaliplatin were kindly pro-
vided by Dr. F. Pinguet (CRLC Val d'Aurelle, France).
cDNA arrays and analysis
Tumor and non tumor colon samples have been collected
following a standardized procedure in order to obtain
high quality RNA [27].
First strand cDNA synthesis was performed using a T7-
linked oligo-dT primer and was followed by second strand
synthesis. Labeled cRNA probes were then generated by
reverse transcription followed by in vitro transcription,
incorporating biotin labels, as part of the standard
Affymetrix protocol. For each sample, the probes were
then hybridized to human genome U133 chips (Affyme-
trix Inc., Santa Clara, CA), corresponding to genes and
expressed sequence tags. Probes were then scanned, and
signal intensity and the detection call for each transcript
was determined using MAS 5.0 Software (Affymetrix Inc.).
Inter-array normalization was performed using a set ofMolecular Cancer 2008, 7:14 http://www.molecular-cancer.com/content/7/1/14
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internal standard genes for the determination of a scaling
factor.
RNA preparation and Q-PCR
All tissue samples were maintained at -196°C (liquid
nitrogen) until RNA extraction. Tissue samples were then
disrupted directly in a lysis buffer using Mixer Mill® MM
300 (Qiagen, Valencia, CA). Total RNA was isolated using
the RNeasy® mini Kit (Qiagen), and subjected to addi-
tional DNAse digestion (Qiagen). RNA quantity was
determined by UV spectroscopy. RNA purity and integrity
were assessed using Agilent RNA 6000 Micro LabChip® Kit
(Agilent Technologies, Palo Alto, CA).
Random primers and dNTP used for the first-strand cDNA
synthesis were purchased from Invitrogen. For real-time
PCR analysis, LightCycler FastStart DNA Master SYBR
Green kit (Roche Molecular Biochemicals, Mannheim,
Germany) and the Light Cycler from Roche Diagnostics
were used. Primer sets for hypoxanthine phosphorybosyl
transferase (HPRT) and PSAT1 were taken from published
sequences and are available upon request. The integrity of
the PCR product reaction was verified by melting curve
analysis. Real-time PCR values were determined by refer-
ence to a standard curve that was generated by Real-time
PCR amplification of serially diluted cDNA using PSAT1
and HPRT primers. Values obtained for levels of PSAT1
were normalized to the levels of HPRT mRNA.
Ectopic PSAT1 expression in SW480-FlpIn cells
PSAT1-expressing cells were generated with the Flp-In sys-
tem (Invitrogen, San Diego, CA). SW480 adenocarci-
noma-FlpIn host cell line was generated according to the
instructions in the Flp-In System manual (Invitrogen).
pcDNA5/FRT/PSAT1 was generated by inserting the
PSAT1 open reading frame (from RZPD) into the
pcDNA5/FRT/V5 vector (Invitrogen). PSAT1 was inserted
into the genomic recombination site by FLP recombinase
enzyme giving the SW480-PSAT1 cell line. Transfection of
an empty vector into Flp-In site gave the SW480-FlpIn cell
line. The stable cell lines were selected for hygromycin B
resistance and cultured in RPMI 1640 (SW480) with 10%
FBS and 50 μg/mL hygromycin B (Invitrogen). Single col-
onies were picked and expanded in selection medium.
Vector inserts and the genomic DNA context in the
selected clones were sequenced to verify the PSAT1
sequence and proper integration into the genetic locus.
Western blot analyses
Non-transfected cells and stably transfected PSAT1 cells
were lysed in SDS buffer (bromophenol blue, 5% β-mer-
captoethanol, 2% SDS, 10% glycerol, 62.5 mM Tris-HCl
pH 6.8). Extracts were sonicated and boiled for 5 min, and
loaded and separated by SDS-PAGE (10%). Proteins were
electrotransferred onto a polyvinylidene difluoride mem-
brane (Amersham Pharmacia Biotech, Uppsala, AB, Swe-
den). Primary antibodies were a chicken polyclonal anti-
human PSAT1 (M-49; GenWay Biotech, San Diego, CA,
USA), a mouse monoclonal anti-Tag V5 (Invitrogen). Sec-
ondary antibodies were a horseradish peroxidase-conju-
gated goat anti-chicken and a horseradish peroxidase-
conjugated anti-mouse (Sigma, St. Louis, MO). The pro-
teins were detected by enhanced chemolumonescence
(ECL) by using the ECL detection system from Amersham
Pharmacia Biotech.
Proliferation assay
Cells (5 × 104) were seeded into six-well plates in tripli-
cate. Six identical plates were seeded for each counting
experiment. Every 24 hours after the initial seed, the cell
number in one of the seven plates was determined.
Mice and xenografting
Female athymic nu/nu mice were purchased from Harlan
France and used at 6-8 weeks of age. For dualxenografts on
the same mouse, 3 × 106 cells of each line were injected
subcutaneously into the left flank for SW480-FlpIn and
right flank for SW480-PSAT1. Tumors were detected by
palpation and measured periodically with calipers. Exper-
imental procedures and handling were performed in a
laminar flow hood. Mice were euthanized when the
tumor volume reached 200 mm3. All experiments and
procedures were carried out under an animal protocol
approved by the French departmental direction of veteri-
naries services. CG and BR are authorized under the num-
bers A34.142 and A34.220.
Cytotoxic assay
Growth inhibition (IC50) assays were performed using the
sulforhodamine B assay as already described [28]. Briefly,
cells were seeded in 96-well plates (2000 cells per well) in
complete medium. After a 48-hour rest, drugs were
applied in a dilution series, each concentration in tripli-
cate: 5-FU from 0 to 8 μM; SN38 from 0 to 10 nM; Oxali-
platin from 0 to 3 μM. After 72 hours, cells were fixed by
adding trichloroacetic acid solution to a final concentra-
tion of 10% and stained with a 0.4% sulforhodamine B
solution in 1% acetic acid (Sigma). The protein-bound
dye was extracted with 10 mM Tris-HCl for determination
of absorbance at 570 nm in an MRX plate reader (Dynex
Inc., Virginia, USA). The IC50 values were determined
graphically from the cytotoxicity curves. Each experiment
was performed three times.
Cell cycle analysis
The cells were seeded in 25 cm2 flasks (4.5 × 104 cells/
flask). After a 72-hour rest, the cells were treated for 72
hours with either 2 μM oxaliplatin, 20 nM SN38, or 10 μM
5-FU; or for 48 hours, with 1, 2, 4, and 8 μM oxaliplatin.
One million cells were pelleted, washed with PBS, fixed inMolecular Cancer 2008, 7:14 http://www.molecular-cancer.com/content/7/1/14
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75% ethanol, treated with 100 μg/mL of RNAse (Boe-
hringer) and stained with 40 μg/mL of propidium iodide.
Analyses were done on a FACScan flow cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA). The cells were gated
on a dot plot display of forward scatter versus side scatter
to extract aggregates. Cell cycle populations were quanti-
fied using WinMDI2.8 histogram analysis software (Phoe-
nix Flow Systems, San Diego, CA).
Apoptosis determination
Cells were seeded in six-well plates (3 × 104 cells/well).
After a 72-hour rest, cells were treated 72 hours with either
2 μM oxaliplatin, 20 nM SN38, or 10 μM 5-FU. The cells
(1 × 106) and corresponding supernatants were labeled
using the Annexin V-FLUOS Staining Kit (Roche Molecu-
lar Biochemicals, Mannheim, Germany) and propidium
iodide (Sigma). Analyses were done on a FACScan flow
cytometer (Becton Dickinson). Annexine V-FLUOS posi-
tive and PI negative cells were quantified using WinMDI
histogram analysis software. For each analysis, the apop-
tosis percentage from the control cells was subtracted.
Immunofluorescence microscopy
The cells were plated in culture dishes containing 12 mm
glass coverslips. One day after oxaliplatin treatment (10
μM), cells on the coverslip were fixed in cold methanol
then gradually rehydrated with PBS. The cells were incu-
bated with an anti-tubulin monoclonal antibody (Sigma).
Secondary antibody was a rhodamine conjugated anti-
mouse. DAPI was used to stain the nucleus. Stained cells
were mounted in Moviol, and images were recorded using
a 63XNA objective on a Leica inverted microscope.
Statistical analysis
To compare PSAT1 RNA expression between the 3 differ-
ent tissues (NC, TC and HM) the Kruskal-Wallis test was
used. Differences were considered significant when p ≤
0.05. The Pearson's test was used to calculate the correla-
tion coefficient.
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